CD8A and graft versus host disease: In particular, MSCs have been shown to immunosuppress both CD4+ and CD8+ T-cells, which is important because they are effector cells in immunological diseases such as graft-versus-host disease (GVHD) [6]; therefore, MSCs have been proposed as potential cells for clinical application.